Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine

Snyder, Susan R. and Hao, Jing and Cavallari, Larisa H. and Geng, Zhi and Elsey, Amanda and Johnson, Julie A. and Mohamed, Zahurin and Chaiyakunapruk, Nathorn and Chong, Huey Yi and Dahlui, Maznah and Shabaruddin, Fatiha Hana and Patrinos, George P. and Mitropoulou, Christina and Williams, Marc S. (2019) Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine. Public Health Genomics, 21 (5-6). pp. 217-227. ISSN 1662-4246, DOI

Full text not available from this repository.
Official URL:


Background/Aims: Economic evaluation is integral to informed public health decision-making in the rapidly growing field of precision and personalized medicine (PM); however, this research requires specialized expertise and significant resources. Generic models are a novel innovation to efficiently address a critical PM evidence shortage and implementation barrier by enabling use of population-specific input values. This is a generic PM economic evaluation model proof-of-concept study for a pharmacogenomic use case. Methods: An 8-step generic economic model development process was applied to the use case of human leukocyte antigen (HLA)-B∗15:02genotyping for prediction of carbamazepine-induced cutaneous reactions, with a user-friendly decision-making tool relying on user-provided input values. This generic model was transparently documented and validated, including cross-validation comparing cost-effectiveness results with 3 country-specific models. Results: A generic pharmacogenomic use case cost-effectiveness model with decision-making tool was successfully developed and cross-validated using input values for 6 populations which produced consistent results for HLA-B∗15:02 screening at country-specific cost-effectiveness threshold values. Differences between the generic and country-specific model results were largely due to differences in model structure and assumptions. Conclusion: This proof on concept demonstrates the feasibility of generic models to provide useful PM economic evidence, supporting their use as a pragmatic and timely approach to address a growing need. © 2019 S. Karger AG, Basel. All rights reserved.

Item Type: Article
Uncontrolled Keywords: Cost-effectiveness; Decision analysis; Modelling; Pharmacogenomics; Precision medicine
Subjects: R Medicine
Divisions: Faculty of Medicine
Depositing User: Ms. Juhaida Abd Rahim
Date Deposited: 14 Jan 2020 02:16
Last Modified: 14 Jan 2020 02:16

Actions (login required)

View Item View Item